Both New and Chronic Potentially Inappropriate Medications Continued at Hospital Discharge Are Associated With Increased Risk of Adverse Events.


Journal

Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062

Informations de publication

Date de publication:
06 2020
Historique:
received: 19 09 2019
revised: 17 12 2019
accepted: 30 12 2019
pubmed: 2 4 2020
medline: 3 3 2021
entrez: 2 4 2020
Statut: ppublish

Résumé

Admission to hospital provides the opportunity to review patient medications; however, the extent to which the safety of drug regimens changes after hospitalization is unclear. To estimate the number of potentially inappropriate medications (PIMs) prescribed to patients at hospital discharge and their association with the risk of adverse events 30 days after discharge. Prospective cohort study. Tertiary care hospitals within the McGill University Health Centre Network in Montreal, Quebec, Canada. Patients from internal medicine, cardiac, and thoracic surgery, aged 65 years and older, admitted between October 2014 and November 2016. Abstracted chart data were linked to provincial health databases. PIMs were identified using AGS (American Geriatrics Society) Beers Criteria®, STOPP, and Choosing Wisely statements. Multivariable logistic regression and Cox models were used to assess the association between PIMs and adverse events. Of 2,402 included patients, 1,381 (57%) were male; median age was 76 years (interquartile range [IQR] = 70-82 years); and eight discharge medications were prescribed (IQR = 2-8). A total of 1,576 (66%) patients were prescribed at least one PIM at discharge; 1,176 (49%) continued a PIM from prior to admission, and 755 (31%) were prescribed at least one new PIM. In the 30 days after discharge, 218 (9%) experienced an adverse drug event (ADE) and 862 (36%) visited the emergency department (ED), were rehospitalized, or died. After adjustment, each additional new PIM and continued community PIM were respectively associated with a 21% (odds ratio [OR] = 1.21; 95% confidence interval [CI] = 1.01-1.45) and a 10% (OR = 1.10; 95% CI = 1.01-1.21) increased odds of ADEs. They were also respectively associated with a 13% (hazard ratio [HR] = 1.13; 95% CI = 1.03-1.26) and a 5% (HR = 1.05; 95% CI = 1.00-1.10) increased risk of ED visits, rehospitalization, and death. Two in three hospitalized patients were prescribed a PIM at discharge, and increasing numbers of PIMs were associated with an increased risk of ADEs and all-cause adverse events. Improving hospital prescribing practices may reduce the frequency of PIMs and associated adverse events. J Am Geriatr Soc 68:1184-1192, 2020.

Sections du résumé

BACKGROUND
Admission to hospital provides the opportunity to review patient medications; however, the extent to which the safety of drug regimens changes after hospitalization is unclear.
OBJECTIVE
To estimate the number of potentially inappropriate medications (PIMs) prescribed to patients at hospital discharge and their association with the risk of adverse events 30 days after discharge.
DESIGN
Prospective cohort study.
SETTING
Tertiary care hospitals within the McGill University Health Centre Network in Montreal, Quebec, Canada.
PARTICIPANTS
Patients from internal medicine, cardiac, and thoracic surgery, aged 65 years and older, admitted between October 2014 and November 2016.
MEASURES
Abstracted chart data were linked to provincial health databases. PIMs were identified using AGS (American Geriatrics Society) Beers Criteria®, STOPP, and Choosing Wisely statements. Multivariable logistic regression and Cox models were used to assess the association between PIMs and adverse events.
RESULTS
Of 2,402 included patients, 1,381 (57%) were male; median age was 76 years (interquartile range [IQR] = 70-82 years); and eight discharge medications were prescribed (IQR = 2-8). A total of 1,576 (66%) patients were prescribed at least one PIM at discharge; 1,176 (49%) continued a PIM from prior to admission, and 755 (31%) were prescribed at least one new PIM. In the 30 days after discharge, 218 (9%) experienced an adverse drug event (ADE) and 862 (36%) visited the emergency department (ED), were rehospitalized, or died. After adjustment, each additional new PIM and continued community PIM were respectively associated with a 21% (odds ratio [OR] = 1.21; 95% confidence interval [CI] = 1.01-1.45) and a 10% (OR = 1.10; 95% CI = 1.01-1.21) increased odds of ADEs. They were also respectively associated with a 13% (hazard ratio [HR] = 1.13; 95% CI = 1.03-1.26) and a 5% (HR = 1.05; 95% CI = 1.00-1.10) increased risk of ED visits, rehospitalization, and death.
CONCLUSIONS
Two in three hospitalized patients were prescribed a PIM at discharge, and increasing numbers of PIMs were associated with an increased risk of ADEs and all-cause adverse events. Improving hospital prescribing practices may reduce the frequency of PIMs and associated adverse events. J Am Geriatr Soc 68:1184-1192, 2020.

Identifiants

pubmed: 32232988
doi: 10.1111/jgs.16413
pmc: PMC7687123
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1184-1192

Subventions

Organisme : CIHR
Pays : Canada

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals, Inc. on behalf of The American Geriatrics Society.

Références

Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Arch Intern Med. 2011 Jun 13;171(11):1013-9
pubmed: 21670370
Ann Pharmacother. 2014 Nov;48(11):1425-33
pubmed: 25159001
Dtsch Arztebl Int. 2012 Feb;109(5):69-75
pubmed: 22368709
JAMA Intern Med. 2018 Mar 1;178(3):375-382
pubmed: 29379953
Int J Clin Pharm. 2019 Feb;41(1):65-73
pubmed: 30610543
Ann Intern Med. 2004 May 18;140(10):795-801
pubmed: 15148066
BMC Fam Pract. 2012 Jul 09;13:56
pubmed: 22697490
Aging Ment Health. 2004 May;8(3):242-8
pubmed: 15203405
BMJ. 1992 Sep 19;305(6855):694-6
pubmed: 1393119
Br J Clin Pharmacol. 2016 Dec;82(6):1660-1673
pubmed: 27511835
Br J Clin Pharmacol. 2016 Sep;82(3):849-57
pubmed: 27136457
Drugs Aging. 2006;23(1):49-59
pubmed: 16492069
Ann Intern Med. 2014 Apr 1;160(7):441-50
pubmed: 24687067
Implement Sci. 2016 Jun 02;11(1):79
pubmed: 27255504
Drug Saf. 2016 Jan;39(1):79-87
pubmed: 26553305
J Clin Pharm Ther. 2013 Oct;38(5):360-72
pubmed: 23550814
Age Ageing. 2014 Nov;43(6):767-73
pubmed: 24637848
BMJ Open. 2018 Jul 19;8(7):e021152
pubmed: 30030316
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
JAMA Intern Med. 2016 Sep 1;176(9):1390-1
pubmed: 27400391
BMJ. 2018 Nov 14;363:k4524
pubmed: 30429122
JAMA. 1995 Jul 5;274(1):29-34
pubmed: 7791255
CMAJ Open. 2016 Jun 22;4(2):E346-51
pubmed: 27398383
Trials. 2012 Aug 27;13:150
pubmed: 22920446
Arch Intern Med. 2005 Jan 10;165(1):68-74
pubmed: 15642877
J Am Geriatr Soc. 2019 Sep;67(9):1843-1850
pubmed: 31250427
J Am Geriatr Soc. 2010 Jan;58(1):83-92
pubmed: 20002509
JAMA. 1995 Jul 5;274(1):35-43
pubmed: 7791256
J Gen Intern Med. 2005 Apr;20(4):317-23
pubmed: 15857487
J Am Med Inform Assoc. 2018 May 1;25(5):482-495
pubmed: 29040609
Geriatr Gerontol Int. 2017 Dec;17(12):2354-2360
pubmed: 28422415
J Clin Epidemiol. 2004 Feb;57(2):131-41
pubmed: 15125622
J Hosp Med. 2008 Mar;3(2):91-102
pubmed: 18438805
Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):53-61
pubmed: 19111015
Br J Gen Pract. 2010 Apr;60(573):e144-55
pubmed: 20353660
J Clin Epidemiol. 1995 Aug;48(8):999-1009
pubmed: 7775999
J Eval Clin Pract. 2010 Feb;16(1):69-75
pubmed: 20367817
Br J Clin Pharmacol. 2016 Nov;82(5):1382-1392
pubmed: 27426227
J Clin Pharm Ther. 1995 Aug;20(4):199-205
pubmed: 8557783
Arch Gerontol Geriatr. 2018 Jan;74:150-154
pubmed: 29107890
J Gen Intern Med. 2007 Jul;22(7):1024-9
pubmed: 17453266
BMJ Open. 2012 Nov 19;2(6):
pubmed: 23166124
J Am Med Inform Assoc. 2014 May-Jun;21(3):391-8
pubmed: 23956015
J Patient Saf. 2013 Sep;9(3):150-3
pubmed: 23965837
BMJ. 2018 Dec 10;363:k4481
pubmed: 30530782
Rev Esp Enferm Dig. 2015 Nov;107(11):652-8
pubmed: 26541654
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372

Auteurs

Daniala L Weir (DL)

Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
Clinical and Health Informatics Research Group, Department of Medicine, McGill University, Montreal, Quebec, Canada.

Todd C Lee (TC)

Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada.

Emily G McDonald (EG)

Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada.

Aude Motulsky (A)

Research Center, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, Quebec, Canada.

Michal Abrahamowicz (M)

Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
Research Center, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Steven Morgan (S)

School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

David Buckeridge (D)

Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
Clinical and Health Informatics Research Group, Department of Medicine, McGill University, Montreal, Quebec, Canada.

Robyn Tamblyn (R)

Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
Clinical and Health Informatics Research Group, Department of Medicine, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH